Drug Interaction of Nifedipine with Ginkgo Flavones in vitro
ZHU Min1， YAO Tong-wei2， ZENG Su2
Author information+
1. Department of Clinical Pharmacy，Second Hospital of Hangzhou City， Hangzhou 310015，China；2.Department of Pharmaceutical Analysis， Zhejiang University， Hangzhou 310006，China
OBJECTIVE To investigate the interaction of nifedipine with ginkgo flavones in vitro.METHODS Flavonoids quercetin,isorhamnetin,keampferol and nifedipine were co-incubated with rat hepatic microsomal at 25 ℃ and the concentrations of flavonoids in residue were determined by HPLC.The IC50 and Ki vaules of quercetin,isorhamnetin and keampferol were observed.The concentrations of nifedipine in residue were determined by HPLC.Metabolism inhibition rates of nifedipine by ginkgo flavones in rat hepatic microsome were observed.RESULTS Nifedipine interacted with ginkgo flavones in rat hepatic microsomal in vitro. CONCLUSION The attention should be paid for the interaction when the preparations of nifedipine is taken with ginkgo flavones.
ZHU Min;YO Tong-wei;ZENG Su.
Drug Interaction of Nifedipine with Ginkgo Flavones in vitro[J]. Chinese Pharmaceutical Journal, 2006, 41(05): 379-381
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CHEN D，ZHU B J. Study on a HPLC method of determination of nifedipine content[J] .Chin J Clin Pharmacol Ther(中国临床药理学与治疗学)2002，7(6)：555-556.
[2] ZHU M， YAO T W， ZENG S. Ginkgo flavones in in vitro metabolism and its clinical application[J] .Acta Pharm Sin(药学学报)，2003，38(12)：938-941.
[3] YAO T W， HU Y Z. RP-HPLC determination of diphenytriazol in rat liver microsomal incubates and its application in in vitro metabolism[J] .Acta Pharm Sin(药学学报)，2002，37(6)：458-461.
[4] CRESPI C L， STRESSER D M. Fluorometric screening for metabolism-based drug-drug interactions[J] .J Pharmacol Toxicol Methods，2000，44(1)：325-331.
[5] TUCKER G T， HOUSTON J B， HUANG S M. Optimizing drug development： strategies to assess drug metabolism/transporter interaction potential-toward a consensus[J] .Clin Pharmacol Ther，2001，70(2)：103-114.
[6] ZHOU S F， KESTELL P， BAGULEY B C. Preclinical factors influencing the relative contributions of phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5，6-dimethylxanthenone-4-acetic acid[J] .Clin Pharmacol Ther，2003，65（1）：109-120.
[7] ZHAO Z G，LUO J S.The pharmacokinetics and bioavailability of nifedipine sustained-release tablets in young healthy volunters[J] .Chin J Clin Pharm(中国临床药学杂志)，1997， 6（1）：8-11.
